Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.

Sparreboom, A; Kehrer, D F S; Mathijssen, R H J; Xie, R; de Jonge, M J A; de Bruijn, P; Planting, A S T; Eskens, F A L M; Verheij, C; de Heus, G; Klaren, A; Zhang, S; Verhaeghe, T; Palmer, P A; Verweij, J

Sparreboom, A; Kehrer, D F S; Mathijssen, R H J; Xie, R; de Jonge, M J A; de Bruijn, P; Planting, A S T; Eskens, F A L M; Verheij, C; de Heus, G; Klaren, A; Zhang, S; Verhaeghe, T; Palmer, P A; Verweij, J.

Affiliation

Sparreboom A; Department of Medical Oncology, Erasmus MC - Daniel den Hoed Cancer Center, 3075 EA, Rotterdam, the Netherlands. Sparreb@mail.nih.gov

Br J Cancer ; 90(8): 1508-15, 2004 Apr 19.

Article in En | MEDLINE | ID: mdl-15083177

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Camptothecin / Antineoplastic Combined Chemotherapy Protocols / Neoplasms Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Br J Cancer Year: 2004 Document type: Article Affiliation country: Países Bajos Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google